|Bid||51.66 x 900|
|Ask||51.99 x 800|
|Day's Range||51.44 - 51.94|
|52 Week Range||44.76 - 55.00|
|Beta (5Y Monthly)||0.40|
|PE Ratio (TTM)||8.80|
|Forward Dividend & Yield||1.91 (3.68%)|
|Ex-Dividend Date||May 03, 2021|
|1y Target Est||63.88|
CureVac, Novavax, Sanofi/GSK, and Valneva all have COVID-19 vaccines that could appear this year.
AstraZeneca (NASDAQ: AZN) and its partner Sanofi (NASDAQ: SNY) recently announced promising results from a late-stage study of nirsevimab in preventing respiratory syncytial virus (RSV) in infants. In this Motley Fool Live video recorded on April 28, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not the two companies can win big with this experimental RSV therapy.
Dr. Gustavo Ferrer, President of Aventura Pulmonary Institute, joins Yahoo Finance’s Kristin Myers and Alexis Christoforous to discuss the latest on the coronavirus pandemic.